skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Issue

A large biotech needed the correct analogs for follow-on biologics PTS in Oncology and Respiratory programs across a range of segments to assess the risk of their portfolio

 

Solution

Our Consultants developed rules for defining each of the relevant segments including:– “First-in-class” and “follow-on”– “Lead” and “Supplemental” indications– “Big Pharma” and “Biotech”We then conducted detailed analysis of thousands of lines of data and classified each program/indication combination for each of the relevant segmentsReferencing the assigned classifications, we used BioMedTracker’s Probability of Success Calculator to determine the average likelihood of approval for all relevant programs in Oncology and Respiratory therapy areas

Outcome

The client was able to use the custom segmentation of data to risk-adjust the forecasts for several of their portfolio assets with probability of success percentages that were most suited to those assetsFree Demonstration

 

 

お問い合わせ

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com


または下記のフォームよりご連絡下さい。

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。